Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
25%
Neutralizing Antibody
17%
Infection
15%
Antibody Response
14%
Nephropathy
13%
Association
13%
Human Immunodeficiency Virus Infection
13%
Vaccine
12%
Human Immunodeficiency Virus 1 Infection
12%
Tenofovir Disoproxil
11%
Seroconversion
11%
Randomized Controlled Trial
11%
Pulse Rate
10%
Placebo
10%
Acute HIV Infection
10%
Cohort Effect
10%
Post-Exposure Prophylaxis
10%
Patient
10%
Tissues
8%
Men Who Have Sex with Men
8%
Symptom
7%
Diagnosis
7%
Analysis
7%
Chronic Kidney Disease
7%
Aciclovir
6%
Kidney
6%
Arm
6%
Cells
6%
Emtricitabine
5%
COVID-19
5%
Raltegravir
5%
T-Helper Cell
5%
HIV Test
5%
Age
5%
DRESS Syndrome
5%
Monotherapy
5%
Efficacy Assessment
5%
Monoclonal Antibody
5%
Experience
5%
Renal Failure
5%
Safety Assessment
5%
Genetic Variability
5%
Young People
5%
Bone
5%
Efavirenz
5%
Vitamin D
5%
Immunogenicity
5%
Posttraumatic Stress Disorder
5%
Sickle Cell Trait
5%
Immunology and Microbiology
Human Immunodeficiency Virus
54%
Neutralization
25%
Human Immunodeficiency Virus Infection
21%
Neutralizing Antibody
17%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Vaccine Efficacy
16%
Breakthrough Infection
16%
COVID-19
15%
Antibody Response
14%
Seroconversion
11%
Pulse Rate
10%
Spike
10%
Immunity
7%
Monoclonal Antibodies
6%
Dose
6%
Tenofovir
5%
Antigen
5%
Cells
5%
Intravenous Immunoglobulin
5%
Immunogenicity
5%
CD32
5%
Immunotherapy
5%
Mucosal-Associated Invariant T Cell
5%
Nursing and Health Professions
Antiretroviral Therapy
11%
Patient
9%
Kidney Disease
8%
Infection
6%
Man
6%
Dose
6%
Analysis
6%
Algorithm
5%
Diagnosis
5%
Human Immunodeficiency Virus Infection
5%
HIV Test
5%
Virus Load
5%
Tenofovir Disoproxil
5%
Estimated Glomerular Filtration Rate
5%
Biobank
5%
Sickle Cell Trait
5%
Genetic Variability
5%
Placebo
5%
Drug Resistance
5%
Kidney Failure
5%
Cladistics
5%
Time
5%
Post Exposure Prophylaxis
5%
Immunotherapy
5%
Clinical Outcome
5%
Syphilis
5%
Ischemic Heart Disease
5%
Epidemiology
5%
